Quality-of-life considerations in the treatment of early-stage breast cancer in the elderly

Drugs and Aging

Volumn 27, Issue 10, 2010, Pages 791-800

  Reimer, Toralf ^a   Gerber, Bernd ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Breast cancer; Elderly; Quality of life.

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EXEMESTANE; FLUOROURACIL; IBANDRONIC ACID; LETROZOLE; METHOTREXATE; PACLITAXEL; PLACEBO; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; DATA BASE; EARLY CANCER; FRAIL ELDERLY; HORMONAL THERAPY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INFORMATION PROCESSING; MASTECTOMY; MEDICAL LITERATURE; MEDLINE; METASTASIS; MULTIPLE CYCLE TREATMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SCORING SYSTEM; SHORT FORM 36; UNSPECIFIED SIDE EFFECT; WELLBEING;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COMORBIDITY; FEMALE; HUMANS; NEOPLASM STAGING; QUALITY OF LIFE;

EID: 77957737765     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11584700-000000000-00000     Document Type: Review

References (54)

1. Robert Koch Institute and Association ofPopulation-based Cancer Registries in Germany, editors. Cancer in Germany, 2003-2004: incidence and trends. 6th ed. Berlin: Robert Koch Institute and Association of Population-based Cancer Registries in Germany, 2008
2. Yancik R, Wesley MN, Ries LAG, et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001; 285: 885-92
3. Montazeri A. Quality oflife data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 2009; 7: 102
4. Di Maio M, Perrone F. Quality oflife in elderly patients with cancer. Health Qual Life Outcomes 2003; 1: 44
5. Montazeri A. Health-related quality oflife in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 2008; 27: 32
6. Albrand G, Terret C. Early breast cancer in the elderly: assessment and management considerations. Drugs Aging 2008; 25: 35-45
7. Terret C, Zulian GB, Naiem A, et al. Multidisciplinary approach to the geriatric oncology patient. J Clin Oncol 2007; 25: 1876-81
8. Clough-Gorr KM, Stuck AE, Thwin SS, et al. Older breast cancer survivors: geriatric assessment domains are asso-ciated with poor tolerance oftreatment adverse effects and predict mortality over 7 years of follow-up. J Clin Oncol 2010; 28: 380-6
9. Muss HB, Tu D, Ingle JN, et al. Efficacy, toxicity, and quality oflife in older women with early-stage breast cancer treated with letrozole or placebo after 5 years oftamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 2008; 26: 1956-64
10. Prescott RJ, Kunkler IH, Williams LJ, et al. A randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older popu-lation: the PRIME trial [letter]. Health Technol Assess 2007; 11: 31
11. International Breast Cancer Study Group. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of Interna-tional Breast Cancer Study Group Trial 10-93. J Clin Oncol 2006; 24: 337-44
12. De Haes JC, Curran D, Aaronson NK, et al. Quality oflife in breast cancer patients aged over 70 years, participating in the EORTC 10850 randomised clinical trial. Eur J Cancer 2003; 39: 945-51
13. Hind D, Wyld L, Beverley CB, et al. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev 2006; 1: CD004272
14. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in interna-tional clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76
15. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and vali-dationofthegeneralmeasure. JClinOncol1993; 11: 570-9
16. Sprangers MA, Groenvold M, Arraras JI, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996; 14: 2756-68
17. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997; 15: 974-86
18. Levine MN, Guyatt GH, Gent M, et al. Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol 1988; 6: 1798-810
19. Giesinger J, Kemmler G, Meraner V, et al. Towards the implementation of quality of life monitoring in daily clin-ical routine: methodological issues and clinical implication. Breast Care 2009; 4: 148-54
20. Guyatt GH, Eagle DJ, Sackett B, et al. Measuring quality of life in the frail elderly. J Clin Epidemiol 1993; 46: 1433-44
21. Overcash J, Extermann M, Parr J, et al. Validity and reliability of the FACT-G scale for use in the older person with cancer. Am J Clin Oncol 2001; 24: 591-6
22. McHorney CA, Ware Jr JE, Lu JF, et al. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patients groups. Med Care 1994; 32: 40-66
23. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 361-70
24. Bernhard J, Hurny C, Coates AS, et al. Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach. Ann Oncol 1997; 8: 825-35
25. Collin C, Wade DT, Davies S, et al. The Barthel ADL Index: a reliability study. Int Disability Study 1988; 10: 61-3
26. Audisio RA, Bozetti F, Gennari R, et al. The surgical management of elderly cancer patients: recommendations of the SIOG surgical task force. Eur J Cancer 2004; 40: 926-38
27. Wildiers H, Kunkler I, Biganzoli L, et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol2007; 8: 1101-15
28. Keating NL, Landrum MB, Ayanian JZ, et al. Consultation with a medical oncologist before surgery and type of sur-gery among elderly women with early-stage breast cancer. J Clin Oncol 2003; 21: 4532-9
29. Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life. Results of the AL-MANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 2006; 95: 279-93
30. Lee JC, Truong PT, Kader HA, et al. Postmastectomy radiotherapy reduces locoregional recurrence in elderly women with high-risk breast cancer. Clin Oncol (R Coll Radiol) 2005; 17: 623-9
31. Smith BD, Haffty BG, Hurria A, et al. Postmastectomy radiation and survival in older women with breast cancer. J Clin Oncol 2006; 24: 4901-7
32. Smith BD, Gross CP, Smith GL, et al. Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst 2006; 98: 681-90
33. Huguenin P, Glanzmann C, LutolfUM. Acute toxicity of curative radiotherapy in elderly patients. Strahlenther On-kol 1996; 172: 658-63
34. Wyckoff J, Greenberg H, Sanderson R, et al. Breast irradiation in the older women: a toxicity study. J Am Geriatr Soc 1994; 42: 150-2
35. Hancke K, Denkinger MD, Konig J, et al. Standard treatment of female patients with breast cancer decreases sub-stantially for women aged 70 years and older: a German clinical cohort study. Ann Oncol 2010; 21: 748-53
36. Lemanski C, Azria D, Gourgon-Bourgade S, et al. Intraoperative radiotherapy in earlystage breast cancer: results of the Montpellier phase II trial. Int J Radiat Oncol Biol Phys 2010; 76: 698-703
37. Goodwin PJ, Black JT, Bordeleau LJ, et al. Health-related quality-of-life measurements in randomized clinical trials in breast cancer: taking stock. J Natl Cancer Inst 2003; 95: 263-81
38. Muss HB, Berry DA, Cirrincione C, et al. Toxicity ofolder and younger patients treated with adjuvant chemotherapy for node positive breast cancer: the Cancer and Leukemia Group B experience. J Clin Oncol 2007; 25: 3699-704
39. Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005; 293: 1073-81
40. Giordano SH, Duan Z, Kuo YF, et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006; 24: 2750-6
41. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, metho-trexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the IBCSG Trial VII. J Clin Oncol 2000; 18: 1412-22
42. Fargeot P, Bonneterre J, Roche H, et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French Adjuvant Study Group 08 trial. J Clin Oncol 2004; 22: 4674-82
43. Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009; 360: 2055-65
44. KornblithAB, Archer L, Lan L, et al. Qualityoflifeofearly stage breast cancer patients 65 years old or older random-ized to standard chemotherapy or capecitabine: a Cancer and Leukemia Group B study (CALGB 49907) [abstract]. Cancer Res 2009; 69 Suppl.: 776s
45. Reimer T, Nitz U, Potenberg J, et al. Capecitabine as adjuvant treatment in elderly patients with early breast can-cer: an interim safety analysis of the ICE study [abstract]. Breast Cancer Res Treat 2006; 100 Suppl. 1: S112
46. Reimer T, Joel B, von Minckwitz G, et al. Quality oflife in elderly patients with early-stage breast cancer treated with ibandronate with or without capecitabine: results of the GBG 32ICE trial [abstract]. Eur J Cancer Suppl 2009; 7:219
47. Smith IE, Procter M, Gelber R, et al. Trastuzumab after adjuvant chemotherapy in older patients [authors' reply]. Lancet 2007; 369: 991-2
48. Cella D, Fallowfield L, Barker P, et al. Quality of life of postmenopausal women in the ATAC (Arimidex, Tamox-ifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006; 100: 273-84
49. Fallowfield L, Cella D, Cuzick J, et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen Alone or in Combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 2004; 22: 4261-71
50. Crivellari D, Sun Z, Coates AS, et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 2008; 26: 1972-9
51. Grimison PS, Stockler M. Quality oflife and adjuvant systemic therapy for breast cancer. Expert Rev Anticancer Ther 2007; 7: 1123-34
52. Ganz PA, Guadagnoli E, Landrum MB, et al. Breast cancer in older women: quality oflife and psychosocial adjustment in the 15 months after diagnosis. J Clin Oncol 2003; 21: 4027-33
53. Clough-Gorr KM, Ganz PA, Silliman RA. Older breast cancer survivors: factors associated with change in emotional well-being. J Clin Oncol 2007; 25: 1334-40
54. Ganz PA, Desmond KA, Leedham B, et al. Quality oflife in long-term, disease-free survivors ofbreast cancer: a follow-up study. J Natl Cancer Inst 2002; 94: 39-49